How AI is supercharging drug development

Artificial intelligence is dramatically reshaping early-stage drug development. Per Axios, a survey of eighty biotech leaders shows AI is slashing preclinical costs and timelines by as much as seventy percent through accelerated computational screening. These 'in silico' platforms simulate thousands of experiments and predict compound behavior, multiplying the number of drug candidates researchers can evaluate. The caveat: AI hasn't yet discovered a drug with FDA approval, and skeptics worry it might miss human variability—the reason ninety percent of new drugs fail in clinical trials.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton